Mobile

A double-blind, randomized, placebo-controlled, multi-center, Clinical Trial of ofatumumab, a fully human monoclonal anti-CD20 antibody in patients with moderate to severe stage Chronic Obstructive Pu...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-003184-31

A double-blind, randomized, placebo-controlled, multi-center, Clinical Trial of ofatumumab, a fully human monoclonal anti-CD20 antibody in patients with moderate to severe stage Chronic Obstructive Pulmonary Disease

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate efficacy of ofatumumab in decreasing inflammation in COPD assessed by bronchial biopsies.

Critère d'inclusion

  • Moderate to severe stage of Chronic Obstructive Pulmonary Disease (COPD)

Liens